about
Insight into the Structural and Biological Relevance of the T/R Transition of the N-Terminus of the B-Chain in Human InsulinTwo-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues.S1 pocket fingerprints of human and bacterial methionine aminopeptidases determined using fluorogenic libraries of substrates and phosphorus based inhibitors.Quantification of homocysteine-related metabolites and the role of betaine-homocysteine S-methyltransferase in HepG2 cells.Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform AOptimized syntheses of Fmoc azido amino acids for the preparation of azidopeptides.Structural Perspectives of Insulin Receptor Isoform-Selective Insulin Analogs.Probing Receptor Specificity by Sampling the Conformational Space of the Insulin-like Growth Factor II C-domain.Computational and structural evidence for neurotransmitter-mediated modulation of the oligomeric states of human insulin in storage granules.Dietary intake of S-(alpha-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats.Rational steering of insulin binding specificity by intra-chain chemical crosslinkingHuman insulin analogues modified at the B26 site reveal a hormone conformation that is undetected in the receptor complex.Synthesis of α-carboxyphosphinopeptides derived from norleucine.Inhibitors of N(alpha)-acetyl-L-ornithine deacetylase: synthesis, characterization and analysis of their inhibitory potency.Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.Dissecting the catalytic mechanism of betaine-homocysteine S-methyltransferase by use of intrinsic tryptophan fluorescence and site-directed mutagenesis.Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities.Converting Insulin-like Growth Factors 1 and 2 into High-Affinity Ligands for Insulin Receptor Isoform A by the Introduction of an Evolutionarily Divergent Mutation.Evaluation of carrier ampholyte-based capillary electrophoresis for separation of peptides and peptide mimetics.Insulin-Insulin-like Growth Factors Hybrids as Molecular Probes of Hormone:Receptor Binding Specificity.Mono-N-acyl-2,6-diaminopimelic acid derivatives: analysis by electromigration and spectroscopic methods and examination of enzyme inhibitory activity.A new colorimetric assay for methionyl aminopeptidases: examination of the binding of a new class of pseudopeptide analog inhibitors.A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor bindingFrom venom peptides to a potential diabetes treatmentCan Arginine Inhibit Insulin Aggregation? A Combined Protein Crystallography, Capillary Electrophoresis, and Molecular Simulation StudyDetermination of pK(a) values of diastereomers of phosphinic pseudopeptides by CZEThe use of Fmoc-Lys(Pac)-OH and penicillin G acylase in the preparation of novel semisynthetic insulin analogsUnusual activity pattern of leucine aminopeptidase inhibitors based on phosphorus containing derivatives of methionine and norleucineA CuAAC-Hydrazone-CuAAC Trifunctional Scaffold for the Solid-Phase Synthesis of Trimodal Compounds: Possibilities and LimitationsThe development of a new class of inhibitors for betaine-homocysteine S-methyltransferasePressure assisted partial filling affinity capillary electrophoresis employed for determination of binding constants of human insulin hexamer complexes with serotonin, dopamine, arginine, and phenol
P50
Q27683744-371091D0-3954-4422-8EC2-A35C4864BA43Q33328683-C171DF26-3C17-41E5-B7AD-B63B80FA642CQ34074856-6589FC60-EFD6-4C38-901A-B2CA5494A32EQ34288550-7FFE7973-65A6-44A4-B454-180988A57103Q35879542-26059F5C-81CC-4C2D-8DB7-E479857B0824Q39000720-BA697632-7A2A-4E9D-8A14-970EB9425DADQ41139895-57C23545-7D22-4291-A364-26FA2332A173Q41549582-5675111A-B6EF-4529-A307-025FDA5846D2Q41816296-E2591428-328E-4639-B728-F2C239878766Q41831504-25454627-B2CA-4BA7-B83F-75A82B678198Q41960756-7FBB0E1F-6A64-4281-A460-A267DA34A46EQ42932932-8FF5EE2F-D259-47B4-B067-704830593AB3Q43116125-432BCAEE-9601-4F5E-86E3-132C1E4AE2B7Q43299713-B45BD601-1520-4479-97CC-050F72C90DCEQ44773788-623370E3-46BA-4890-BE63-CF75EC004250Q44880403-4DAD8D49-8767-43B4-8F8A-CA948776DCEAQ47367789-D7B8B62F-5990-4EB4-8F02-ECF7928B262CQ52613594-7F5B0F1C-8B72-45E9-8842-F45ACC92C427Q52694140-EDCDC591-DDED-41FD-B923-C1B2C8C3558EQ53098315-64B55632-4F32-42B8-9BD6-63B42F8D4219Q54282206-F85470AD-411A-4476-BD70-25909E81A408Q54459619-FC784B93-A82F-4893-9BFA-CC6EF9CAB58BQ58741987-3C905660-481D-44BD-A8A4-3A4DF02E330EQ61796590-D2584CE5-DC5D-4BAD-8615-E0FCCFFCAC2EQ62788841-E434CB1D-5A85-417B-9325-3C423C3AF15DQ79323974-1EE70CDC-6EAA-4F11-82CD-5A58E62873B7Q80162910-FFD6DB20-CA19-4C28-B554-03229BD5781DQ84478769-86BE1D60-42DB-47CB-8DE5-E13B28E19B8DQ86578994-46A4C61D-3EC8-40ED-96F7-02287D78D11EQ86883406-061DF1F0-921F-4B9A-8DF0-30DDF5F525FFQ91235406-65BA20CA-049B-4606-A078-A38488A521CC
P50
description
biochemik
@cs
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jiri Jiracek
@ast
Jiri Jiracek
@es
Jiri Jiracek
@nl
Jiří Jiráček
@cs
Jiří Jiráček
@en
type
label
Jiri Jiracek
@ast
Jiri Jiracek
@es
Jiri Jiracek
@nl
Jiří Jiráček
@cs
Jiří Jiráček
@en
prefLabel
Jiri Jiracek
@ast
Jiri Jiracek
@es
Jiri Jiracek
@nl
Jiří Jiráček
@cs
Jiří Jiráček
@en
P214
P21
P214
P31
P496
0000-0003-3848-2773
P569
1965-10-05T00:00:00Z